Delivery Order SPE2DB20D2014-SPE2DB26FA24H
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $19,175.67. This is a firm fixed-price delivery order with no set-aside designation, issued competitively, and scheduled for completion by October 15, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Dupixent 300 mg/2 ml pens valued at $17,659.92, with completion scheduled for November 3, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $13,120.76. This is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, open-market award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency (DLA) awarded a $22,848.80 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by August 5, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $35,600.20 on August 29, 2025, for Dupixent 300 mg/2 mL pen auto-injectors. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by September 2, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $14,525.26. This firm fixed-price delivery order, which is expected to be completed by August 4, 2025, was competitively awarded with no set-aside designation. The product will be delivered to the prime contractor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,527.70 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $11,758.26. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,709.46 on August 12, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB26FA24HDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $8,030.96. This firm fixed-price delivery order is scheduled for completion by November 3, 2025, and represents a non-set-aside competitive procurement. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. Dupixent is a prescription medication used to treat atopic dermatitis, asthma, and other allergic conditions, reflecting the critical pharmaceutical supply needs of the military healthcare system. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen regularly fulfills federal medical procurement requirements through the DLA Medical Supply Chain, supplying a broad portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support Defense Health Agency and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 10/31/25 |